Emergent Biosolutions EBS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.8M-90.0% | —— | $51.2M-55.4% | -$12M+95.8% | $68M+656% | ||
| $23.5M-7.5% | $23.5M-9.6% | $23.4M-11.4% | $23.5M-17.5% | $25.4M-9.0% | ||
| $1.9M+26.7% | $5.3M+23.3% | $4.8M+109% | $4.6M-16.4% | $1.5M-74.6% | ||
| -$4.5M-124% | —— | -$10.2M— | —— | $18.6M+252% | ||
| $1.8M-21.7% | $2.6M+18.2% | $2.5M— | $2.4M-52.0% | $2.3M-66.7% | ||
| -$800K-167% | -$1M— | -$2.2M+83.1% | -$1M+97.5% | -$300K— | ||
| $38.9M-46.9% | -$51.9M-167% | $71.6M+187% | -$118.5M— | $73.3M+46.6% | ||
| -$15.8M-818% | —— | $17.6M-2.2% | $24.7M+90.0% | $2.2M-51.1% | ||
| -$14.4M-167% | —— | -$4M+82.6% | -$10.4M-500% | -$5.4M-125% | ||
| -$1.8M+75.0% | —— | —— | -$21.1M-881% | -$7.2M-755% | ||
| $500K+105% | —— | —— | -$19.7M+88.1% | -$9.5M-258% | ||
| $3.9M-65.5% | -$9.1M-250% | —— | —— | $11.3M+265% | ||
| $3.2M+1,167% | $4.1M+373% | $1.2M— | $200K— | -$300K+98.5% | ||
| $4.6M+155% | -$6.3M— | $6.2M-41.0% | —— | -$8.4M-152% | ||
| -$33.8M-202% | $77.7M— | $0-100% | $106.4M— | -$11.2M+82.1% | ||
| $2.4M-33.3% | $3.9M+129% | $3.4M-41.4% | $2.9M-37.0% | $3.6M-66.7% | ||
| $0-100% | —— | —— | $100K— | $38.1M— | ||
| -$2.4M-104% | —— | —— | $17.2M+474% | $59.5M+651% | ||
| $9M— | $9.1M— | $8.9M— | $6.9M— | $0— | ||
| $400K— | -$1M— | $200K— | $800K— | $0— | ||
| $2.8M+460% | $400K+33.3% | $300K0.0% | $200K0.0% | $500K+25.0% | ||
| -$11.4M-2,750% | -$113.9M— | -$15.9M+91.2% | -$6.4M+87.4% | -$400K-101% | ||
| $0+100% | —— | —— | $1M— | -$700K— | ||
| -$47.6M-201% | —— | —— | $118.2M+1,578% | $47.2M+244% | ||
| $13.1M-21.6% | $8M-2.4% | $16.9M-14.6% | $8.1M-44.1% | $16.7M-22.3% | ||
| $5.3M-63.4% | $12.5M— | $10.9M+13.5% | $2.1M-84.4% | $14.5M+16.9% | ||
| $1.8M-21.7% | $2.6M+18.2% | $2.5M— | $2.4M-52.0% | $2.3M-66.7% | ||
| -$800K-167% | -$1M— | -$2.2M+83.1% | -$1M+93.7% | -$300K— | ||
| -$20.2M+37.3% | —— | —— | —— | -$32.2M+3.3% | ||
| $4.6M+155% | -$6.3M— | $6.2M-41.0% | —— | -$8.4M-152% | ||
| $400K-50.0% | $800K-27.3% | $700K+16.7% | $800K+14.3% | $800K-33.3% | ||
| $500K+105% | —— | —— | -$19.7M+88.1% | -$9.5M-258% | ||
| $3.9M-65.5% | -$9.1M-250% | —— | —— | $11.3M+265% | ||
| $0+100% | —— | —— | -$20M— | -$30M— | ||
| $0-100% | —— | —— | —— | $5M— | ||
| $0-100% | —— | —— | $100K— | $38.1M— | ||
| —— | $950K— | $950K— | $950K— | $950K— | ||
| $0-100% | $0-100% | -$800K— | $700K0.0% | $100K— | ||
| $1M-33.3% | —— | —— | $700K— | $1.5M-54.5% | ||
| -$8.4M+11.6% | $7.3M+232% | —— | —— | -$9.5M— | ||
| $3.2M+1,167% | $4.1M+373% | $1.2M— | $200K— | -$300K+98.5% | ||
| -$36.2M-145% | $73.8M— | $0-100% | $103.5M— | -$14.8M+79.8% | ||
| -$36.2M-145% | $73.8M— | $0-100% | $103.5M— | -$14.8M+79.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Emergent Biosolutions generate?
- Emergent Biosolutions (EBS) generated $150.3M in operating cash flow over the trailing twelve months.
- What is Emergent Biosolutions's free cash flow?
- After $12.6M of capital expenditures, Emergent Biosolutions's free cash flow was $141.1M over the trailing twelve months, up 310.0% year over year.
- Where does Emergent Biosolutions's cash flow data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
